Characterization of a human coagulation factor Xa-binding site on Viperidae snake venom phospholipases A2 by affinity binding studies and molecular bioinformatics
2007
Identifying How Snake Venom Affects Blood Clotting
publication
Evidence: high
Author Information
Author(s): Faure Grazyna, Gowda Veerabasappa T, Maroun Rachid C
Primary Institution: Institut Pasteur
Hypothesis
The study aims to characterize the binding site of Viperidae snake venom phospholipases A2 on human coagulation factor Xa.
Conclusion
The study identified several strong FXa-binding SVPLA2s that disrupt blood coagulation by interacting with FXa through a non-catalytic mechanism.
Supporting Evidence
- Viperidae venom phospholipases A2 can inhibit blood coagulation.
- Binding studies showed that certain SVPLA2s have high affinity for FXa.
- Experimental data correlated with molecular docking simulations to identify binding sites.
Takeaway
Some snake venoms can stop blood from clotting by sticking to a part of the blood's clotting system, which could help create new medicines.
Methodology
The study used surface plasmon resonance (SPR) and in vitro tests to measure the interaction between snake venom phospholipases A2 and human coagulation factor Xa.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website